BIOGEN INC. (BIIB): what the price assumes

boothcheck covers BIOGEN INC. (BIIB) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/BIIB

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 8.1% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.8%); the inversion above states its own rate.

Per-Model Detail (n=13)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• The multiple sclerosis franchise that built this company is eroding on schedule rather than collapsing: TYSABRI revenue "decreased $49.6 million, from $1,715.0 million in 2024 to $1,665.4 million in 2025, or 2.9%, primarily due to increased competition in rest of world, including the impacts from a biosimilar entrant of TYSABRI in Europe."
• Close to a fifth of revenue is a share of drugs Biogen does not sell, booked as its cut of pre-tax profits on RITUXAN, GAZYVA and LUNSUMIO plus a "gross 3.0 % royalty on net sales of OCREVUS outside the U.S.", which means that slice carries almost no cost and almost no control.
• Second-quarter results land on July 29, 2026, and the number that matters is LEQEMBI, where Biogen books half of a launch that produced $168 million of global sales in the first quarter.

Bull Case

Start with the cash, because for a company whose headline story is decline, the cash is doing something unusual. Biogen converted roughly $2.42 billion of free cash flow out of $9.94 billion of revenue over the trailing year. That is close to a quarter of every dollar of revenue arriving as cash the company can actually spend, from a business the market is treating as a melting ice cube. Working capital was "$5.6 billion as of December 31, 2025", and the share count has moved by about 0.1% a year over the last four years. No dilution. No financial engineering to flatter per-share numbers either.

That combination says something about how management reads its own position. A team that believed the franchise was finished would be buying back stock at $202.19 to shrink the denominator while the numerator fell. A team that believed the pipeline was the answer would spend the money on assets. Biogen has done the second, including the HI-Bio acquisition disclosed in the financial statements, and has funded it while carrying modest borrowings against a business that throws off cash every quarter.

The revenue base is more durable than the decline rate suggests, and the reason is structural. Roughly a fifth of it comes from the anti-CD20 arrangement with Roche, where Biogen's share consists of "net sales to third-party customers less applicable costs to manufacture, third-party royalty expense, distribution, selling and marketing expense and joint development expense incurred by Genentech and the Roche Group." Somebody else runs the sales force. Biogen books the profit share. Add the "gross 3.0 % royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis" and a meaningful part of the income statement is annuity-shaped rather than commercially exposed.

Meanwhile the legacy products are declining slowly, not falling off a cliff. Rest of world SPINRAZA revenue "decreased $26.2 million, from $947.5 million in 2024 to $921.3 million in 2025, or 2.8%", U.S. SPINRAZA was flat, and global interferon revenue slipped "from $968.0 million in 2024 to $945.6 million in 2025, or 2.3%". Declines in the low single digits from products with decades of prescriber habit behind them buy a lot of time for something new to arrive.

The something new is Alzheimer's. Biogen recognizes "our 50.0 % share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal", and that line grew from "approximately $177.7 million and $59.9 million, respectively" across the two most recent years, roughly a tripling off a small base. The bear objection is fair: it is small, and it is half of small. The bull answer is that Alzheimer's is the largest untreated neurological market in medicine, Biogen owns half of the first approved disease-modifying therapy in it, and the cost of that option is already sunk. At today's price the buyer is paying about twelve times operating profit for the existing business and getting the Alzheimer's position without an obvious charge for it.

Bear Case

Roche is the competitor that matters, and the awkward part is that Biogen is on its payroll. OCREVUS took the multiple sclerosis market Biogen used to own, and Biogen's compensation for that is "a gross 3.0 % royalty on net sales of OCREVUS outside the U.S." with a defined expiry: the royalty period runs "11 years from the first commercial sale of OCREVUS on a country-by-country basis." A 3% royalty on someone else's success is not a substitute for owning the franchise, and it stops.

Underneath that, the generic and biosimilar pressure is already in the reported numbers rather than pending. TYSABRI fell 2.9% in 2025 "primarily due to increased competition in rest of world, including the impacts from a biosimilar entrant of TYSABRI in Europe", the interferons fell 2.3%, and the company is in litigation over the U.S. version of the same threat, having "filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A." The anti-CD20 income has the same exposure from the other direction: the filing notes several other anti-CD20 molecules "including biosimilar products, that have been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets." Biosimilars referencing RITUXAN are already available in the U.S. Regulatory attention is not letting up either, with the company disclosing that in "January 2026 we received a request for information regarding TECFIDERA from the European Commission Directorate-General for Competition."

Set against the cohort, the growth problem is stark. Biogen's revenue has been growing at roughly 1% a year. GILD is running a 34.9% operating margin on revenue of $29.7B growing 3.5%. AMGN sits at a 28.4% operating margin on $37.2B growing 9.1%. VRTX carries a 38.3% operating margin on $12.2B growing 10.1%. Even BMRN, at less than a third of Biogen's revenue, is growing near 9.9%. Biogen is the slowest grower in its own comparable set, and slow growth in pharmaceuticals is rarely a plateau. It is usually the middle of a slope.

Now the price. The static methods do not reach it. The asset-value approaches, which measure the equity against its book and the returns earned on that book, leave the price above them by a factor of about two. The earnings-power approaches, which capitalize what the company currently earns with nothing credited for growth, sit at about half of what the stock costs. Peer multiples come closer but stay below. Only the forward-growth methods reach $202.19, and the route they take there is worth naming: they hold today's enterprise-value-to-EBITDA multiple, in the mid forties, flat all the way out to the end of the projection while free cash flow grows about 1% a year. Freeze a mid-forties multiple for five years on a business growing that slowly and you have not valued it. You have assumed the answer.

The Alzheimer's option does not close that gap on current numbers. Collaboration revenue from LEQEMBI of "approximately $177.7 million" in the most recent year is under 2% of total revenue, and Biogen keeps half of it. For that line to offset a declining base it needs to grow by roughly an order of magnitude, which requires diagnosis infrastructure, infusion capacity and payer behavior all moving together over years. The clinical question is largely settled; the commercial one is not.

The balance sheet limits the damage without preventing it. Net borrowings sit near 3.7 billion dollars including lease obligations, against free cash flow of about $2.42 billion a year, so there is no solvency event waiting here. What there is instead is the slower problem: a company earning a return on book equity in the mid single digits against a cost of equity above 9%, which is the arithmetic of value quietly leaking out of a strong balance sheet rather than blowing up.

Valuation

A buyer at $202.19 is purchasing three different things, and only one of them is a normal drug business. About 72% of revenue is product Biogen sells itself. Roughly 19% is a share of profits on drugs Roche sells. The remaining slice is contract manufacturing and royalties. The three carry different margins, different durability and different competitive exposure, so the consolidated multiple is an average of situations rather than a description of one.

On the whole-company view the market is paying about twelve times operating profit. That is low enough that the price sits below what a business with a steadily shrinking profit stream would warrant, which is the bound rather than a solved figure: it says the price embeds contraction, and it does not say how much. Against the sector the multiple sits in the lower half of the peer range, so the market is not treating Biogen as a growth pharmaceutical company. It is treating it as a run-off with optionality attached.

Where the methods disagree is instructive, because they disagree about which of the three businesses matters. The asset-value methods put the price at roughly twice their central estimate. The reason is arithmetic: Biogen earns a mid-single-digit return on its book equity while the return shareholders require sits several points higher, so the book erodes instead of compounding. The earnings-power methods, which capitalize current earnings with no growth, place the price near double where they land. Peer multiples come closer, with the price about 28% above them. Only the forward-growth methods reach the price, and they get there by holding today's enterprise-value-to-EBITDA multiple flat across the whole projection on a free cash flow base of about $2.4 billion growing at 1%.

That is a specific bet, not a general one. It is not that Biogen grows. It is that the market keeps paying today's multiple for a business that does not, which is the same as saying the terminal value carries the whole case.

The cohort makes the size of the gap concrete. GILD converts 34.9% of revenue into operating profit; VRTX converts 38.3%; AMGN 28.4%. Those are whole-company comparables rather than segment-matched peers, so the read is directional, but the direction is consistent: the companies Biogen is measured against convert more of their revenue and grow it faster, and the market prices them accordingly.

Solvency takes the tail risk off the table without adding to the case. Working capital was "$5.6 billion as of December 31, 2025", net borrowings including leases sit near 3.7 billion dollars, and free cash flow of about $2.42 billion covers that comfortably. Share count has been flat for four years, so nothing is being taken from existing holders and nothing is being returned to them through the count either. The balance sheet buys time; what it does not do is decide whether the Alzheimer's franchise arrives before the multiple sclerosis one finishes eroding.

Catalysts

Second-quarter results are due before the market opens on July 29, 2026. The reference point is the March quarter, which produced revenue of $2.48 billion, with global LEQEMBI sales of $168 million, of which Biogen recognizes half as collaboration revenue. Management also reported that 78% of LEQEMBI patients remained on treatment at eighteen months, which matters more than the quarterly sales figure: persistence on a chronic infusion therapy is what turns a launch into an annuity.

The nearer-term swing factor is the subcutaneous formulation. An at-home injection removes the infusion-chair bottleneck that has capped LEQEMBI uptake since approval, and the regulatory timeline for it is the item to listen for on the call. Until that lands, LEQEMBI volume is limited by health-system capacity rather than by demand or by evidence.

On the other side of the ledger, the company disclosed that in "January 2026 we received a request for information regarding TECFIDERA from the European Commission Directorate-General for Competition", and the TYSABRI biosimilar litigation against Sandoz and Polpharma remains open in Delaware. Neither is likely to resolve on any particular quarter, but both sit on the same side of the scale as the legacy revenue decline, and both are the kind of item that shows up as a discrete charge rather than a gradual trend.

Peer Cohorts (Per Segment, With Filing Citations)

Biogen (consolidated) (reported)

• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …case was removed to the U.S. District Court for the Eastern District of Texas. Also in November 2025, BMS and certain Sanofi entities sued the Texas AG in Texas state court in Travis County, Texas to enjoin the Texas AG's lawsuit. No trial dates have been scheduled in either case. SECURITIES LITIGATION Celgene…
• FY2025 10-K: …aGVHD acute graft-versus-host disease MS Multiple Sclerosis Amgen Amgen Inc. MSI-High microsatellite instability-high AML acute myeloid leukemia MyoKardia MyoKardia, Inc. Amylin Amylin Pharmaceuticals, Inc. MZL marginal zone lymphoma ANDA abbreviated New Drug Application NAV net asset value ASC Accounting Standards…
• GILD (GILEAD SCIENCES, INC.)
• FY2025 10-K: …with third parties for the research, development and commercialization of certain products and product candidates. The collaborations involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial…
• FY2025 10-K: …in 2023, primarily related to upfront payments. We also made various purchases of Arcellx shares for which we recorded an equity investment of $ 299 million on our Consolidated Balance Sheets in 2023. As of December 31, 2025, the investment is included in Prepaid and other current assets. The companies share…
• AMGN (Amgen Inc.)
• FY2025 10-K: …of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2022. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or…
• FY2025 10-K: …31, 2023 on February 14, 2024 and incorporated herein by reference.) 10.17.1 Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of…
• BMRN (BioMarin Pharmaceutical Inc)
• FY2025 10-K: 31, 2025: Consolidated Statements of Income 89 Consolidated Statements of Comprehensive Income 90 Consolidated Balance Sheets 91 Consolidated Statements of Stockholders' Equity 92 Consolidated Statements of Cash Flows 93 Notes to Consolidated Financial Statements 94 80 Table of Contents Exhibit Index Exhibit Number…
• FY2025 10-K: …with the SEC on February 28, 2008 as Exhibit 10.30 to the Company's Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. 10.9…
• VRTX (VERTEX PHARMACEUTICALS INC / MA)
• FY2025 10-K: …President, Tax and Treasury from 2011 to June 2018. Prior to Celgene, Mr. Biller was General Counsel, Chief Tax Officer and Secretary at Bunge Limited, a global publicly traded agriculture and food company. Earlier in his career he held various leadership roles at Alcon, Inc. and was a partner at Hopkins & Sutter and…
• FY2025 10-K: …December 31, 2025 and 2024 , we had goodwill of $ 1.1 billion on our consolidated balance sheets. F-31 VERTEX PHARMACEUTICALS INCORPORATED Notes to Consolidated Financial Statements (Continued) K. Additional Balance Sheet & Cash Flow Information Cash, Cash Equivalents and Restricted Cash Presented in Consolidated…
• BNTX (BioNTech SE)
• FY2025 20-F: …arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years. Segment Information Decisions with respect to business…
• FY2025 20-F: …register B of the Mainz Local Court under the number HRB 48720. The accompanying consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries and have been prepared on a going concern basis in accordance with the IFRS Accounting Standards as issued…
• JAZZ (Jazz Pharmaceuticals plc)
• FY2025 10-K: …for 81 % of gross accounts receivable, including ESSDS, which accounted for 41 % of gross accounts receivable, ASD, which accounted for 16 % of gross accounts receivable and McKesson, which accounted for 11 % of gross accounts receivable. As of December 31, 2024, five customers accounted for 80 % of gross accounts…
• FY2025 10-K: …Term Loans were refinanced into a new tranche of U.S. dollar term loans Tricare program Tricare Retail Pharmacy program Tris Pharma Tris Pharma, Inc. TSC tuberous sclerosis complex TSR total shareholder return U.K. United Kingdom U.K. Bribery Act U.K. Bribery Act of 2010 U.S. United States of America U.S. GAAP U.S.…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …ImmunoGen were $ 578 million and operating losses attributable to ImmunoGen were $ 682 million, inclusive of $ 349 million of cash-settled, post-closing expense for ImmunoGen employee incentive awards, $ 179 million of inventory fair value step-up amortization and $ 157 million of intangible asset amortization.…
• FY2025 10-K: …acquisition date was not significant. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $ 44 million for the year ended December 31, 2024 and were included in SG&A expense in the consolidated statements of earnings. Acquisition of ImmunoGen, Inc. On…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.